Purinergic Signalling: Therapeutic Developments.
Purinergic Signalling: Therapeutic Developments.
复制标题
DOI：
10.3389/fphar.2017.00661
复制
发表时间：
2017
影响因子：
5.6
通讯作者：
Burnstock G
中科院分区：
文献类型：
--
作者：
Burnstock G
嘌呤能信号传导，即，1972年提出了核苷酸作为细胞外信号分子的作用。然而，直到20世纪90年代初，嘌呤和嘧啶的受体亚型被克隆和表征，这一概念才被广泛接受，其中包括P1（腺苷）受体的4种亚型、P2X离子通道受体的7种亚型和P2Y G蛋白偶联受体的8种亚型。早期的研究主要关注嘌呤能信号的生理学、药理学和生物化学。最近，重点一直放在病理生理学和治疗潜力。早期认识到P1受体激动剂用于治疗室上性心动过速，A2A受体拮抗剂有望用于治疗帕金森病。氯吡格雷是一种P2Y12拮抗剂，广泛用于治疗血栓形成和中风，阻断P2Y12受体介导的血小板聚集。地夸磷索是一种长效P2Y2受体激动剂，目前正用于治疗干眼症。已经开发了口服生物可利用且在体内稳定的P2X3受体拮抗剂，并且目前正在临床试验中用于治疗慢性咳嗽、膀胱失禁、内脏痛和高血压。正在研究P2X7受体的拮抗剂用于治疗炎性疾病，包括神经退行性疾病。其他研究正在进行中，用于治疗骨质疏松症、心肌梗塞、肠易激综合征、癫痫、动脉粥样硬化、抑郁症、自闭症、糖尿病和癌症的嘌呤能药物。
Purinergic signalling, i.e., the role of nucleotides as extracellular signalling molecules, was proposed in 1972. However, this concept was not well accepted until the early 1990’s when receptor subtypes for purines and pyrimidines were cloned and characterised, which includes four subtypes of the P1 (adenosine) receptor, seven subtypes of P2X ion channel receptors and 8 subtypes of the P2Y G protein-coupled receptor. Early studies were largely concerned with the physiology, pharmacology and biochemistry of purinergic signalling. More recently, the focus has been on the pathophysiology and therapeutic potential. There was early recognition of the use of P1 receptor agonists for the treatment of supraventricular tachycardia and A2A receptor antagonists are promising for the treatment of Parkinson’s disease. Clopidogrel, a P2Y12 antagonist, is widely used for the treatment of thrombosis and stroke, blocking P2Y12 receptor-mediated platelet aggregation. Diquafosol, a long acting P2Y2 receptor agonist, is being used for the treatment of dry eye. P2X3 receptor antagonists have been developed that are orally bioavailable and stable in vivo and are currently in clinical trials for the treatment of chronic cough, bladder incontinence, visceral pain and hypertension. Antagonists to P2X7 receptors are being investigated for the treatment of inflammatory disorders, including neurodegenerative diseases. Other investigations are in progress for the use of purinergic agents for the treatment of osteoporosis, myocardial infarction, irritable bowel syndrome, epilepsy, atherosclerosis, depression, autism, diabetes, and cancer.
登录
查看更多内容
影响因子：
2.2
作者：
Akimoto, Masaki;Yunoue, Shingo;Arima, Naomichi
通讯作者：
Arima, Naomichi
影响因子：
7.3
作者：
Able, S. L.;Fish, R. L.;Katugampola, S. D.
通讯作者：
Katugampola, S. D.
对细胞外ATP的反应改变会增强对乙酰氨基酚肝毒性。
DOI：
10.1186/1478-811x-11-10
发表时间：
2013-02-05
期刊：
Cell communication and signaling : CCS
影响因子：
--
作者：
Amaral SS;Oliveira AG;Marques PE;Quintão JL;Pires DA;Resende RR;Sousa BR;Melgaço JG;Pinto MA;Russo RC;Gomes AK;Andrade LM;Zanin RF;Pereira RV;Bonorino C;Soriani FM;Lima CX;Cara DC;Teixeira MM;Leite MF;Menezes GB
通讯作者：
Menezes GB
影响因子：
7.7
作者：
Aikin RA
通讯作者：
Aikin RA
影响因子：
3.8
作者：
Acevedo, CG;Huambachano, A;Contreras, E
通讯作者：
Contreras, E